Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • UCLA • Rheumatology • NCI-CCC Breast Tumor Board Question • Breast Cancer, Non-metastatic • Immune Checkpoint Inhibitor
Is there evidence for development of more severe autoimmune toxicities for young patients vs older patients on immune checkpoint inhibitors?
As immune checkpoint inhibitors have expanded into the neoadjuvant breast cancer setting, severe and unexpected autoimmune toxicities may cause delays in therapy. Are young women (30s-40s) more likely to get autoimmune toxicities?
Answer from: Medical Oncologist at Community Practice
I am not aware of any. In my practice, I have realized that younger patients are getting more severe autoimmune toxicities like immune-related cardiomyopathy and adrenal insufficiency.
Sign in or Register to read more